A Phase I Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 using the Intra-patient Escalation Dosing Regimen in Patients with Advanced Uveal Melanoma
A study for patients with advanced Uveal Melanoma using study drug IMCgp100
Sponsor: Immunocore
Enrolling: Male and Female Patients
IRB Number: AAAQ4601
U.S. Govt. ID: NCT02570308
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This is a Phase I study of a weekly intra-patient escalation dose regimen with IMCgp100 in patients with metastatic uveal melanoma (mUM). To help decide whether or not patients can take part in a research study looking at a new form of treatment for advanced uveal melanoma, their blood need to first be tested to determine their Human Leukocyte Antigen (HLA) type. To be able to take part in the research study, patients need to be HLA type A2 positive. The sponsor believes that this type of cancer is more likely to respond to this new type of treatment if they are also HLA type A2 positive. The study doctor does not know the patients' HLA type so he/she will need to do a blood test to find out. About half of the general population are HLA type A2 positive.
This study is closed
Richard Carvajal, MD
Do You Qualify?
Have you been diagnosed with Uveal Melanoma? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator